Creative Medical Technology Holdings, Inc. (CELZ) Stock Price & Analysis

Creative Medical Technology Holdings, Inc. (CELZ) fell 2.70% to USD 1.08 as of September 8, 2026 at 22:54 UTC, according to Nexqual real-time market data.

CELZ last closed at USD 1.08; the session ranged USD 1.07–1.12 on volume of 135,282 shares. Market capitalization is —, with a 52-week range of USD 0.62–6.25 (NCM). Source: Nexqual, September 8, 2026 at 22:54 UTC.

Key Statistics (as of September 8, 2026 at 22:54 UTC)

Technical Analysis (CELZ)

Nexqual's technical model rates CELZ "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of September 8, 2026 at 22:54 UTC.

From Creative Medical Technology Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-20)

Key Strengths & Strategy (as disclosed to the SEC)

• Greenstone's developments were confirmed by an independent, industry-leading research firm.   In October 2022, we announced the development of our AlloStem™ Clinical Cell Line (CELZ-200), a proprietary allogenic cell line which includes a Master Cell Bank and a Drug Master File.
• Fast Track status enables us to benefit from accelerated FDA interactions, rolling Biologics License Application (BLA) submissions, and eligibility for priority review—potentially expediting the path to market and patient access.   In October, 2025 we launched the BioDefense Veterans Initiative, believed to be a first-of-its-kind national program to combat the devastating long-term effects of toxic burn pit exposure among U.S. service members.
• Our patent portfolio is currently composed of seven issued patents and thirty nine pending patent applications filed in the United States with the USPTO as follows:   Issued Patents       Pending Patent Applications       Patent Purchase and License Agreements   Lower Back Pain Patent Purchase.
• The following is a general overview of the laws and regulations pertaining to our business.     FDA Regulation of Stem Cell Treatment and Products   The FDA regulates the manufacture of human stem cell treatments and associated products under the authority of the Public Health Service Act (or PHS Act), and the Federal Food, Drug, and Cosmetic Act (or FDCA).

Partnerships

• The strategic collaboration is expected to extend the progress made on our proprietary hypoimmune iPSC technology, including our iPSC-derived pancreatic islet cells.
• In August 2023, the Company paid CMH $100,000 related to the filing of an IND with the FDA per the terms of the agreement.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 22:54 UTC. This page is informational and not investment advice.